Please ensure Javascript is enabled for purposes of website accessibility

Why Amgen Is Down Nearly 7% Today

By James Brumley – Aug 4, 2021 at 3:30PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biopharma name cautioned shareholders that it's still suffering from a pandemic hangover, but investors should think bigger-picture.

What happened

Amgen (AMGN -0.21%) shares were trading 6.8% lower late Wednesday following a second-quarter earnings beat that was marred by lowered full-year guidance.

So what

The biopharma outfit turned $6.5 billion worth of sales into per-share earnings of $4.38 for the three-month stretch ending in June, both up from year-ago figures, and both topping consensus estimates. Analysts were only modeling a profit of $4.09 per share and revenue of $6.46 billion.

But the challenges created by the pandemic linger. The company lowered its per-share guidance for 2021 to a range of between $8.84 and $9.90, according to generally accepted accounting principles (GAAP), down from prior guidance of between $9.11 and $10.71 per share, as, according to executive vice president Murdo Gordon, "patient visits and lab test procedure trends continue to improve but remain below pre-COVID-19 levels." Fewer doctor-patient visits crimps sales of Amgen's drugs like migraine treatment Aimovig, psoriasis drug Otezla, and arthritis drug Enbrel.

A lab technician working on a pipette.

Image source: Getty Images.

Now what

The market's response to contracted guidance is understandable, but perhaps unmerited. Amgen shares have already been a subpar performer of late, currently trading where they were as of November 2019, and now back to breakeven for the year. Most of the company's prospective challenges were already baked in.

Given this context -- coupled with the fact that Amgen still boasts one of the better portfolios in the pharmaceutical business -- Wednesday's stumble is arguably more of a buying opportunity than a hint of what the future holds. The current dividend yield of 2.9% is also uncharacteristically high for the industry, bolstering the bullish argument. Buyers just need to be prepared for continued volatility.

James Brumley has no position in any of the stocks mentioned. The Motley Fool recommends Amgen. The Motley Fool has a disclosure policy.

Stocks Mentioned

Amgen Stock Quote
$284.91 (-0.21%) $0.60

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.